Clinical Trial: A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06880354) titled 'A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia' on March 11.

Brief Summary: This is a single-arm, open-label, phase I dose-escalation clinical study to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual-target CAR T cell injection in r/r AML subjects.

Study Start Date: March 31

Study Type: INTERVENTIONAL

Condition: Acute Myeloid Leukemia

Intervention: DRUG: CLL1 and CD38 Dual-Target CAR-T Cell Injection

This product is a lentiviral gene-modified autologous chimeric antigen receptor T-cell ...